Spots Global Cancer Trial Database for hematopoietic cell transplantation
Every month we try and update this database with for hematopoietic cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | NCT05039073 | Recurrent Class... Refractory Clas... | Brentuximab Ved... Hematopoietic C... Nivolumab Quality-of-Life... Questionnaire A... | 12 Years - | Emory University | |
| Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation | NCT04727827 | Hematopoietic C... Oncology | Pharmacogenomic... | 18 Years - | Wake Forest University Health Sciences | |
| Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia | NCT01050036 | Leukemia, Myelo... | autologous hema... | 15 Years - 65 Years | Asan Medical Center | |
| Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) | NCT00693927 | Hematologic Mal... | Unmanipulated P... CD8-depleted PB... | - 70 Years | University of Liege | |
| Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | NCT03411031 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia | NCT02807883 | Acute Lymphobla... | Blinatumomab Hematopoietic C... | 1 Year - 70 Years | M.D. Anderson Cancer Center | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases | NCT04083183 | Non-Malignant N... | Astatine At 211... Fludarabine Cyclophosphamid... Lapine T-Lympho... Total-Body Irra... Hematopoietic C... Mycophenolate M... Sirolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 49 Years | Fred Hutchinson Cancer Center | |
| The Effect of an Online ACT Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation | NCT06266182 | Hematopoietic C... Acceptance and ... | Acceptance and ... Education | 18 Years - | University of Social Sciences and Humanities, Warsaw | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen | NCT01328496 | Hematologic Mal... Disorder Relate... Hematopoietic M... | Preparative Reg... | - 21 Years | St. Jude Children's Research Hospital | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | NCT03674047 | Other Cancer | ruxolitinib | 18 Years - 75 Years | Massachusetts General Hospital | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | NCT04708054 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | Busulfan Cladribine Fludarabine Pho... Hematopoietic C... Thiotepa Venetoclax | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Cognitive Training Intervention and Attitudes Towards Genetics | NCT03094026 | Cognitive Impai... Hematologic Neo... Hematopoietic C... | Lumosity Lumosity (waitl... | 21 Years - | University of Alabama at Birmingham | |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | NCT04262843 | Acute Lymphobla... Acute Myeloid L... High Risk Myelo... Myelodysplastic... | Cyclophosphamid... Fludarabine Fludarabine Pho... Granulocyte Col... Hematopoietic C... Intensity-Modul... Mycophenolate M... Tacrolimus | 12 Years - 60 Years | City of Hope Medical Center | |
| A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers | NCT02409121 | Leukemia Lymphoma Brain Tumor | Education infor... | 10 Years - 75 Years | University of Michigan Rogel Cancer Center | |
| A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia | NCT04822766 | Acute Myeloid L... | Hematopoietic s... Best chemothera... | 65 Years - 75 Years | Assistance Publique - Hôpitaux de Paris | |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | NCT06287944 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an... | 18 Years - | City of Hope Medical Center | |
| GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide | NCT04622956 | Graft Vs Host D... Hematopoietic N... | Methotrexate In... | 18 Years - 70 Years | University of Sao Paulo General Hospital | |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | NCT04214249 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | NCT03426969 | Primary Myelofi... Secondary Myelo... | Cyclophosphamid... Filgrastim Fludarabine Pho... Hematopoietic C... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT04994808 | Acute Myeloid L... Myelodysplastic... | Clofarabine Fludarabine Hematopoietic C... Total-Body Irra... Treosulfan | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Selecting a Favorable KIR Donor in Unrelated HCT for AML | NCT01288222 | Acute Myelogeno... | KIR genotype | - | Masonic Cancer Center, University of Minnesota | |
| Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation | NCT03276481 | Multiple Myelom... | Oral microbiota... Comprehensive c... Measurement of ... Surveys assessi... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | NCT02484391 | Granulocytic Sa... Recurrent Adult... | 6,8-Bis(benzylt... Cytarabine Hematopoietic C... Mitoxantrone Hy... | 18 Years - | Wake Forest University Health Sciences | |
| Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. | NCT06409767 | Leukemia Lymphoma Multiple Myelom... | Real-time calcu... | 18 Years - | University Hospital, Angers | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | NCT04375631 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut... | Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp... | 18 Years - | Fred Hutchinson Cancer Center | |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant | NCT04898790 | Leukemia Lymphoma Multiple Myelom... MDS Myeloproliferat... | CHAMPS-II adapt... | 60 Years - | University of Nebraska | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients | NCT02648932 | Acute Myeloid L... Myelodysplastic... | Haplo-Cord Tran... Matched Unrelat... | 18 Years - | University of Chicago | |
| Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen | NCT01328496 | Hematologic Mal... Disorder Relate... Hematopoietic M... | Preparative Reg... | - 21 Years | St. Jude Children's Research Hospital | |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | NCT02484391 | Granulocytic Sa... Recurrent Adult... | 6,8-Bis(benzylt... Cytarabine Hematopoietic C... Mitoxantrone Hy... | 18 Years - | Wake Forest University Health Sciences | |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT03583424 | Hematopoietic C... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Tran... | Carmustine Cytarabine Etoposide Hematopoietic C... Melphalan Venetoclax | 19 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| HCT Versus CT in Elderly AML | NCT00766779 | Acute Myeloid L... | hematopoietic c... Non-Transplant ... | 60 Years - 75 Years | European Society for Blood and Marrow Transplantation | |
| Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia | NCT03476330 | Fanconi Anemia Squamous Cell C... | Quercetin (diet... | 2 Years - | Children's Hospital Medical Center, Cincinnati | |
| Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | NCT00410982 | Leukemia Lymphoma Myeloma | Busulfan Gemcitabine Melphalan Hematopoietic C... Rituximab for P... Palifermin | 18 Years - 69 Years | M.D. Anderson Cancer Center | |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies | NCT00521859 | Hematologic Mal... | Cloretazine Fludarabine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | NCT06128070 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Biospecimen Col... Chest Computed ... Echocardiograph... Hematopoietic C... Methotrexate Multigated Acqu... Ruxolitinib Pho... Tacrolimus | 2 Years - 22 Years | City of Hope Medical Center | |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | NCT04262843 | Acute Lymphobla... Acute Myeloid L... High Risk Myelo... Myelodysplastic... | Cyclophosphamid... Fludarabine Fludarabine Pho... Granulocyte Col... Hematopoietic C... Intensity-Modul... Mycophenolate M... Tacrolimus | 12 Years - 60 Years | City of Hope Medical Center | |
| Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. | NCT06409767 | Leukemia Lymphoma Multiple Myelom... | Real-time calcu... | 18 Years - | University Hospital, Angers | |
| Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation | NCT03276481 | Multiple Myelom... | Oral microbiota... Comprehensive c... Measurement of ... Surveys assessi... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant | NCT04898790 | Leukemia Lymphoma Multiple Myelom... MDS Myeloproliferat... | CHAMPS-II adapt... | 60 Years - | University of Nebraska | |
| Selecting a Favorable KIR Donor in Unrelated HCT for AML | NCT01288222 | Acute Myelogeno... | KIR genotype | - | Masonic Cancer Center, University of Minnesota | |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | NCT06287944 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an... | 18 Years - | City of Hope Medical Center | |
| Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | NCT03317899 | Non-Hodgkin's L... Plasma Cell Mye... | Hematopoietic C... Tbo-filgrastim Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | NCT06128070 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Biospecimen Col... Chest Computed ... Echocardiograph... Hematopoietic C... Methotrexate Multigated Acqu... Ruxolitinib Pho... Tacrolimus | 2 Years - 22 Years | City of Hope Medical Center | |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies | NCT00521859 | Hematologic Mal... | Cloretazine Fludarabine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | NCT04708054 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | Busulfan Cladribine Fludarabine Pho... Hematopoietic C... Thiotepa Venetoclax | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia | NCT01050036 | Leukemia, Myelo... | autologous hema... | 15 Years - 65 Years | Asan Medical Center | |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases | NCT04083183 | Non-Malignant N... | Astatine At 211... Fludarabine Cyclophosphamid... Lapine T-Lympho... Total-Body Irra... Hematopoietic C... Mycophenolate M... Sirolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 49 Years | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
